CI-966

From Food & Medicine Encyclopedia

CI-966
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number 123441-03-2
PubChem 60729
DrugBank
ChemSpider 54747
KEGG


CI-966 is an experimental drug that has been studied for its potential effects on the central nervous system. It is classified as a GABA reuptake inhibitor, which means it inhibits the reuptake of gamma-aminobutyric acid (GABA), a key inhibitory neurotransmitter in the brain.

Mechanism of Action[edit]

CI-966 works by inhibiting the reuptake of GABA into neurons and glial cells, thereby increasing the levels of GABA in the synaptic cleft. This action enhances the inhibitory effects of GABA, which can lead to a reduction in neural excitability and has potential therapeutic effects for conditions such as epilepsy and anxiety disorders.

Potential Therapeutic Uses[edit]

Research has suggested that CI-966 may be useful in the treatment of various neurological disorders, including:

Side Effects[edit]

As an experimental drug, the side effects of CI-966 are not fully understood. However, potential side effects may include:

Research and Development[edit]

CI-966 is still under investigation, and more research is needed to fully understand its efficacy and safety profile. Clinical trials are ongoing to determine its potential benefits and risks in treating various neurological conditions.

See Also[edit]

References[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.